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Abstract: Mesenchymal stem cells (MSCs) have been used in cell 
replacement therapies for connective tissue damage, but also can 
stimulate wound healing through paracrine activity. In order to further 
understand the potential use of MSCs to treat dogs with neurological 
disorders, this study examined the paracrine action of adipose-derived 
canine MSCs on neuronal and endothelial cell models.  
 
The culture-expanded MSCs exhibited a MSC phenotype according to plastic 
adherence, cell morphology, CD profiling and differentiation potential 
along mesenchymal lineages. Treating the SH-SY5Y neuronal cell line with 
serum-free MSC culture-conditioned medium (MSC CM) significantly 
increased SH-SY5Y cell proliferation (P < 0.01), neurite outgrowth (P = 
0.0055) and immunopositivity for the neuronal marker βIII-tubulin (P = 
0.0002). Treatment of the EA.hy926 endothelial cell line with MSC CM 
significantly increased the rate of wound closure in endothelial cell 
scratch wound assays (P = 0.0409), which was associated with 
significantly increased endothelial cell proliferation (P < 0.05) and 
migration (P = 0.001). Furthermore, canine MSC CM induced endothelial 
tubule formation in EA.hy926 cells in a soluble basement membrane matrix. 
Hence, this study has demonstrated that adipose-derived canine MSC CM 
stimulated neuronal and endothelial cells probably through the paracrine 
activity of MSC-secreted factors. This supports the use of canine MSC 
transplants or their secreted products in the clinical treatment of dogs 
with neurological disorders and provides some insight into possible 
mechanisms of action. 
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Abstract 21 
Mesenchymal stem cells (MSCs) have been used in cell replacement therapies for 22 
connective tissue damage, but also can stimulate wound healing through paracrine activity. In 23 
order to further understand the potential use of MSCs to treat dogs with neurological 24 
disorders, this study examined the paracrine action of adipose-derived canine MSCs on 25 
neuronal and endothelial cell models.  26 
 27 
The culture-expanded MSCs exhibited a MSC phenotype according to plastic 28 
adherence, cell morphology, CD profiling and differentiation potential along mesenchymal 29 
lineages. Treating the SH-SY5Y neuronal cell line with serum-free MSC culture-conditioned 30 
medium (MSC CM) significantly increased SH-SY5Y cell proliferation (P < 0.01), neurite 31 
outgrowth (P = 0.0055) and immunopositivity for the neuronal marker βIII-tubulin (P = 32 
0.0002). Treatment of the EA.hy926 endothelial cell line with MSC CM significantly 33 
increased the rate of wound closure in endothelial cell scratch wound assays (P = 0.0409), 34 
which was associated with significantly increased endothelial cell proliferation (P < 0.05) and 35 
migration (P = 0.0001). Furthermore, canine MSC CM induced endothelial tubule formation 36 
in EA.hy926 cells in a soluble basement membrane matrix. Hence, this study has 37 
demonstrated that adipose-derived canine MSC CM stimulated neuronal and endothelial cells 38 
probably through the paracrine activity of MSC-secreted factors. This supports the use of 39 
canine MSC transplants or their secreted products in the clinical treatment of dogs with 40 
neurological disorders and provides some insight into possible mechanisms of action. 41 
 42 
Keywords: Angiogenesis; Central nervous system repair; Mesenchymal stem/stromal cell; 43 
Nerve growth; Secretome44 
Introduction 45 
Mesenchymal stem cells (MSCs) were originally identified as stem/progenitor cells 46 
that differentiated to form connective tissues, e.g. as bone-forming osteoblasts and cartilage-47 
forming chondrocytes, and the bone marrow stroma supporting haemopoiesis (Friedenstein et 48 
al., 1974; Haynsworth et al., 1992; Pittenger et al., 1999). This led to MSCs being considered 49 
important candidates for cell replacement therapies for damaged connective tissues or to 50 
support bone marrow haemopoeitic stem cell transplantation (Young et al., 1998; Gupta et 51 
al., 2012; De Bari et al., 2013; Giannotti et al., 2013; Wu et al., 2013). However, it has 52 
become clear that MSCs play wider roles in tissue regeneration and wound healing as they 53 
secrete growth factors and cytokines that can stimulate endogenous cells present at wound 54 
sites (Chen et al., 2008; Park et al., 2009). This secretory function can augment tissue repair 55 
through trophic, anti-inflammatory or immunodulatory activity for various conditions, 56 
including heart disease (Gallini et al., 2015), liver damage (Berrardis et al., 2015; Owen and 57 
Newsome, 2015), skin wounds (Otero-Venas and Falanga, 2016) and central nervous system 58 
(CNS) damage (Teixeira et al., 2013). Furthermore, MSCs have been isolated from tissue 59 
sources other than bone marrow, including adipose tissues, which is an attractive source, due 60 
to its relative ease of removal (Sousa et al., 2014). The breadth of MSC activity and their 61 
ready availability has broadened the attractiveness of MSC-based therapies in regenerative 62 
medicines (Correa and Caplan, 2011).  63 
 64 
 The use of MSCs to promote wound healing after spinal cord injury (SCI) is a 65 
particular case in point. We and others have reported that human MSC secrete factors that 66 
promote neurite outgrowth (Neuhuber et al., 2005; Crigler L. et al., 2006; Wright et al., 2007, 67 
Nakano et al., 2010; Wright et al., 2010 and 2014) and endothelial cell proliferation and 68 
migration in vitro (Walter et al., 2015) and that MSC transplantation was associated with 69 
decreased inflammation, increased neural survival, increased axonal regeneration and 70 
improved functional recovery after SCI in vivo (Ankeny et al., 2004; Neuhuber et al., 2005; 71 
Himes et al., 2006; Nakajima et al., 2012). This research supports MSC transplantation as a 72 
cell therapy for various conditions, including CNS damage, with a number of human trials 73 
currently underway or in development. In dogs, MSC-based cell therapies for CNS damage, 74 
particularly SCI, also have been explored. In an experimental model of SCI, MSC transplants 75 
were associated with increased neural survival and repair, increased axonal conductance 76 
velocity, reduced inflammation and increased functional recovery (Lim et al., 2007; Ryu et 77 
al., 2012). MSC transplants similarly were associated with increased function in dogs 78 
suffering from natural SCI following intervertebral disc herniation (Chung et al., 2013; Penha 79 
et al., 2014; Sarmento et al., 2014; Besalti et al., 2015; Kim et al., 2016). Examining the 80 
efficacy of cell transplantation for naturally occurring CNS damage in dogs in this manner is 81 
an important step in the translation of experimental studies to human and animal cell 82 
therapies (Jeffery et al., 2006, 2011; Hoffman and Dow, 2016). However, for new cell 83 
therapies in dogs to be applied optimally and for this translational knowledge to human 84 
treatment to be complete, it is essential that researchers establish the mode of activity of 85 
canine MSCs. Therefore, in this study we examined whether canine MSCs isolated from 86 
adipose tissue exert a neurotrophic and angiogenic activity through their secretome. 87 
 88 
Materials and methods 89 
MSC isolation and growth 90 
Institutional approval was provided for this study (University of Chester Faculty of 91 
Science and Engineering Research Ethics Committee: 060/16/CW/BS, 18 May 2016). 92 
Following owner and veterinary surgeon consent for research, canine adipose tissue-derived 93 
MSCs were isolated and cultured from surgically extracted inguinal fat pads of dogs 94 
undergoing MSC transplantations for the treatment of joint pathology. MSCs were isolated 95 
by collagenase digestion of the tissue for 2 h at 37 oC (0.2% Type A Collagenase, 96 
Worthington Biochemical), selected through their preferential adhesion to tissue culture 97 
plastic, as reported previously (Vieira et al., 2010; Kohli et al., 2015), and cultured in 98 
Dulbecco’s modified Eagle medium/F12 (DMEM/F12) supplemented with 10% fetal bovine 99 
serum and 1% penicillin/ streptomycin (Life Technologies) in a humidified atmosphere of 5% 100 
CO2 with 95% air at 37 oC. Cultures were routinely passaged at 70-80% confluence using 101 
0.25% trypsin-EDTA (Life Technologies). All experimental procedures were performed 102 
using MSC cultures at passages 3-5.  103 
 104 
MSC characterisation 105 
MSC phenotype was examined according to the International Society for Cell 106 
Therapy (ISCT) criteria (Dominici et al., 2006), which are as follows: (1) cell adherence to 107 
tissue culture plastics; (2) adipogenic, osteogenic and chondrogenic differentiation potential; 108 
and (3) an immunoprofile for CD markers that includes immunonegativity for CD34 and 109 
CD45 and immunopositivity for CD44 and CD90, as assessed by flow cytometry (Appendix: 110 
Supplementary material).  111 
 112 
MSC culture-conditioned medium (MSC CM) 113 
MSCs were seeded at a density of 1.5 x 106 cells in T75 tissue culture flasks in 114 
standard culture medium for 24 h to permit cell adhesion, then the medium was discarded and 115 
the cultures washed in PBS prior to feeding with 15 mL of DMEM/F12 medium 116 
supplemented with 1% ITS, 1% non-essential amino acids and 1% penicillin/streptomycin, 117 
but without any serum present. Cultures were then incubated at 37 ºC in a humidified 118 
atmosphere of 5% CO2 for 3 days, when the MSC culture-conditioned medium (MSC CM) 119 
was collected, filtered with a sterile filter (0.20 µm, Minisart), aliquoted and stored at -80 ºC. 120 
Control medium (i.e. serum free DMEM/F12 with the same supplements, but with no cells 121 
present) was similarly incubated in T75 culture flasks for 3 days, harvested, filtered and 122 
stored. Under serum-free conditions, there was no evident loss of cell viability and greater 123 
than 98% of cells in all cultures were viable at day 3 (by trypan blue exclusion).  124 
 125 
The effects of MSC CM on SH-SY5Y neuronal cells  126 
The human neuroblastoma cell line SH-SY5Y was used to assess neurotrophic 127 
activity of canine MSC CM, as has been performed previously with human MSC CM 128 
(Wright et al., 2010; Pires et al., 2014; Appendix: Supplementary material). This was due to a 129 
lack of available canine neuronal models, but also because we and other researchers have 130 
found similar responses to MSC secretomes in cell assays using MSCs and responder cells of 131 
the same and different species, i.e. humans, chickens and rodents (Neuhuber et al., 2005; 132 
Wright et al., 2010; Pires et al., 2014) suggesting conservation of paracrine activity.   133 
 134 
The effects of MSC CM on EA.hy926 endothelial cells 135 
The human Ea.hy926 endothelial cell line was used as a model to examine any 136 
angiogenic activity of canine MSC CM, due to a lack of available canine endothelial cells and 137 
also because these cells have been used previously to test human MSC CM (Walter et al., 138 
2015). EA.hy926 cell assays were performed to measure endothelial cell proliferation, 139 
endothelial cell migration and endothelial tubule formation (Appendix: Supplementary 140 
material). 141 
 142 
Statistical analysis 143 
At least three independent experiments were performed for all analysis, i.e. using 144 
MSCs and MSC CM derived from at least three different dogs vs. at least three separate 145 
control media with 3-5 replicates for each experiment. Data were examined for normal 146 
distributions and then analysed by two-way ANOVA, independent samples Student’s t tests 147 
or Mann Whitney U tests, according to whether data was distributed normally or not. All data 148 
has been presented as mean ± standard error. P values <0.05 was considered statistically 149 
significant. Statistical analysis was performed using GraphPad Prism7 (GraphPad Software). 150 
 151 
Results 152 
 Characterisation of canine MSCs 153 
At passage 3-5, cultures of canine MSCs were plastic-adherent, displayed a stromal 154 
appearance and had the capacity to undergo differentiation towards adipogenic, osteogenic 155 
and chondrogenic lineages (Fig. 1A). For adipogenic and osteogenic differentiation, there 156 
was no evident loss of cell viability, however for chondrogenic pellet cultures some cell death 157 
was apparent, but nonetheless there was also clear evidence of extracellular metachromatic 158 
staining with toluidine blue, indicative of glycosaminoglycan deposition and chondrogenic 159 
differentiation. CD immunoprofiling demonstrated that canine MSCs were largely 160 
immunonegative for CD34 (0.3 ± 0.6%) and CD45 (0.1 ± 0.3%) and immunopositive for 161 
CD44 (87.7 ± 9.3%) and CD90 (94.1 ± 9.7%; Fig. 1B). These results demonstrate that the 162 
canine cells that had been culture-expanded from adipose tissue met the necessary criteria of 163 
the ISCT (Dominici et al., 2006) to be considered MSCs. 164 
 165 
Canine MSC secreted factors promote SH-SY5Y cell proliferation and neuronal 166 
differentiation 167 
Treating SH-SY5Y cells with canine MSC CM promoted their proliferation and 168 
neuronal differentiation, as determined by viable cell numbers, neurite outgrowth and 169 
immunoreactivity for βIII-tubulin (Fig. 2). There was an increase in the number of SH-SY5Y 170 
cells present, and in their extent of neurite outgrowth (Fig. 2A), which were immunopositive 171 
for βIII-tubulin (Fig. 2B) in MSC CM vs. control media. SH-SY5Y neurite length/cell (P = 172 
0.0055) and the proportions of SH-SY5Y cells that were βIII-tubulin immunopositive (P = 173 
0.0002) were significantly greater in MSC CM than in control medium (Fig. 2C). The 174 
increase in SH-SY5Y cell number in MSC CM vs. control medium was also significant and 175 
confirmed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays (P 176 
< 0.01) (Fig. 2C). 177 
 178 
Canine MSC secreted factors promote EA.hy926 endothelial cell migration, proliferation and 179 
tubule formation  180 
The effects of canine MSC CM on EA.hy926 cells were examined by scratch assay, 181 
time-lapse live cell image analysis, MTT assay and tubule formation with Matrigel. In 182 
EA.hy926 endothelial scratch wound assays, wound closure was markedly increased in MSC 183 
CM compared to control media (Fig. 3A). Using live cell image analysis, we found that 184 
EA.hy926 cells closed the scratch wounds significantly more quickly in MSC CM vs. control 185 
media (P = 0.0409) by a combination of increased cell migration and cell proliferation (Fig. 186 
3B). The trophic effects of MSC CM on EA.hy926 endothelial cell proliferation were 187 
confirmed by MTT assays for the numbers of viable cells, which was significantly increased 188 
after 2 days culture in MSC CM compared with control media (P = 0.0019) (Fig. 3B). We 189 
then tested whether MSC CM could promote blood vessel formation, as delineated by 190 
endothelial tubule formation in Matrigel assays and digitised image analysis (Fig. 4). As 191 
shown (Fig. 4A), culturing EA.hy926 endothelial cells on Matrigel did not give rise to any 192 
marked tubule formation unless MSC CM was present, in which case both the total length of 193 
the endothelial tubules that formed (P = 0.0082) and the number of endothelial tubule branch 194 
points present (P = 0.0307) were significantly increased in MSC CM compared to control 195 
media (Fig. 4B). 196 
 197 
Discussion 198 
MSCs have been investigated for their wound healing activity, with potential 199 
applications for a wide variety for conditions including CNS damage. MSCs exert paracrine 200 
effects on cells involved in CNS repair, including neuronal cells, endothelial cells and 201 
immune cells (Neuhuber et al., 2005; Crigler et al., 2006; Wright et al., 2007; Wright et al., 202 
2010; Nakajima et al., 2012; Wright et al., 2014; Walter et al., 2015). Furthermore, MSC 203 
transplantation in animal models of SCI was associated with enhanced neural regeneration, 204 
modulation of immune responses and improved functional outcomes (Ankeny et al., 2004; 205 
Neuhuber et al., 2005; Himes et al., 2006; Nakajima et al., 2012). Hence, MSC transplants 206 
are considered an attractive treatment option to help overcome CNS damage, particularly SCI 207 
(Wright et al., 2011). 208 
 209 
Dogs, like humans, can suffer from SCI and paralysis, either through accidental 210 
trauma or following herniation of the intervertebral disc. Furthermore, other researchers have 211 
recently demonstrated that transplantation of autologous culture-expanded olfactory 212 
ensheathing cells (OECs) might be of benefit to dogs with SCI (Granger et al., 2012). This 213 
not only is of use to veterinary medicine, but also helps inform the development of clinical 214 
human SCI studies (Jeffery et al., 2006, 2011). Therefore, with a view to developing MSC 215 
transplants for dogs with CNS damage and to further understand the potential mechanisms of 216 
action of MSC following transplantation, we investigated whether canine MSCs exerted 217 
paracrine wound healing activities similar to human and rodent MSCs.  218 
 219 
After initially characterizing MSCs from the inguinal fat pads of dogs according to 220 
the ISCT criteria (Dominici et al., 2006), we used established in vitro assays with responder 221 
cell lines to test their paracrine activity. We report that MSC CM was trophic for SH-SY5Y 222 
neuronal cells, and stimulated neurite outgrowth and neuronal differentiation. MSC CM also 223 
was trophic for EA.hy926 endothelial cells, enhanced their migratory behaviour and 224 
stimulated endothelial tubule formation, all of which indicate angiogenic activity, although 225 
clearly further in vivo testing would help confirm this  (Auerbach et al., 2003). These data 226 
support the application of MSC transplantation in dogs with SCI, as well as other CNS 227 
injuries, as enhanced neuronal survival, axonal growth and the appropriate regulation of 228 
angiogenesis are thought to represent important aspects of repair processes (Oudega et al., 229 
2012; Quertainmont et al., 2012). 230 
 231 
The mechanisms of action of the canine MSC secretome warrant further investigation. 232 
In other species, MSCs are known to secrete a plethora of growth factors, cytokines and 233 
extracellular matrix (ECM) components (Park et al., 2009; Walter et al., 2010, 2015).  These 234 
include a variety of soluble neurotrophic factors, including nerve growth factor, brain-derived 235 
neurotrophic factor and glial-derived neurotrophic factor, as well as pleiotrophic factors that 236 
also can stimulate nerve outgrowth, such as fibroblast growth factors 1 and 2 (FGF1 and 237 
FGF2) and stromal derived factor 1 (Crigler et al., 2006; Wilkins et al., 2009; Nakano et al., 238 
2010; Hseih et al., 2013; Kingham et al., 2014; Lin et al., 2014). Similarly, MSCs are known 239 
to secrete soluble angiogenic factors, including FGFs, hepatocyte growth factor and the 240 
highly potent vascular endothelial growth factor (Rehman et al., 2004; Cai et al., 2007). In 241 
addition, at least some of the ECM components that have been identified in human MSC CM, 242 
particularly fibronectin and laminin, form a stimulatory substratum for nerve growth and also 243 
endothelial cells (Kapur and Katz, 2013; Walter et al., 2010, 2015). The identification of 244 
growth factors and ECM in the secretome of canine MSCs is somewhat hampered by a lack 245 
of canine specific antibodies, but it is highly likely that many of the factors present in the 246 
MSC secretomes of other species are similarly secreted by canine MSCs. Additionally, they 247 
could play active roles in the neurostimulatory and angiogenic effects seen in SH-SY5Y 248 
neuronal cells and EA.hy926 endothelial cells. A similar profile of growth factors and ECM 249 
components has been reported in MSC secretomes with cells cultured from a variety of tissue 250 
sources (Walter et al., 2010, 2015; Kapur and Katz, 2013; Bronckaers et al., 2014). Also, 251 
there is a high degree of conservation across species for at least some growth factors and 252 
cytokines that have been examined at the molecular level (Wen et al., 1993; Scheerlinck, 253 
1999). Nonetheless, one recent study found species-specific differences in the secretome and 254 
paracrine activity of canine and equine MSCs, particularly when cultured in serum free 255 
conditions (Clarke et al., 2016). Therefore, although it might be considered more likely that 256 
the canine MSC secretome would have even greater trophic effects on canine responder cells, 257 
a potential caveat to our study is that we tested canine MSC secretomes on human responder 258 
cell lines only. Further studies of canine neuronal and endothelial cells, as they become 259 
available, and the identification of MSC secreted factors in MSC CM, are required. 260 
 261 
In veterinary medicine, the uptake of MSC-based therapies has been relatively low, 262 
although canine MSC transplants were used recently in the treatment of some natural injury 263 
and disease conditions, including tendon repair (Case et al., 2013), osteoarthritis (Black et al., 264 
2007, 2008; Vilar et al., 2013, 2014; Cuevo et al., 2014), inflammatory bowel disease (Perez-265 
Merino et al., 2015a,b) and non-infectious CNS inflammation (Zeira et al., 2015). There also 266 
have been a number of studies of MSC transplants in canine SCI. In the clinical studies of 267 
SCI to date, MSC transplants have been associated with some benefits including improved 268 
gait and neurological function (Penha et al., 2014; Sarmento et al., 2014; Besalti et al., 2015; 269 
Kim et al., 2016). However, the mechanisms of action for these reported benefits remain 270 
poorly understood. In rodent models of SCI, MSC transplants have been suggested to exert a 271 
wide variety of effects that might enhance spinal cord repair and function (Ide et al., 2010; 272 
Vaquero and Zurita 2011; Teixeira et al., 2013), including their differentiation to form 273 
replacement neural cells (Deng et al., 2014), albeit contentiously (Wright et al., 2011); 274 
immunomodulatory/anti-inflammatory activity and increased neuronal survival (Ankeny et 275 
al., 2004; Crigler et al., 2006; Nakajima et al., 2012), directing axons that bridge across the 276 
SCI lesion site (Ankeny et al., 2004); secretion of neurotrophic factors and angiogenic factors 277 
to enhance axonal regeneration (Ankeny et al., 2004; Neuhuber et al., 2005; Lu P et al., 2005; 278 
Nakajima et al., 2012); and angiogenic responses (Zeng et al., 2011; Kingham et al., 2014). 279 
Here, to our knowledge, our study has provided the first evidence that canine MSCs promote 280 
nerve growth and endothelial cell proliferation, migration and tubule formation, probably 281 
through the secretion of neurotrophic and angiogenic factors. These findings support the 282 
hypothesis that MSC transplants can promote increased neuronal function in dogs with CNS 283 
damage, including SCI, due to their paracrine activity on nerves and blood vessels in the 284 
vicinity of the wound site. Further, this study supports the concept that cell transplants in 285 
dogs with SCI, whether MSCs or OECS, provide an important natural model for the 286 
development of human cell-based therapies.  287 
  288 
Conclusions  289 
In this study, we have demonstrated for the first time that canine MSCs stimulate 290 
neuronal growth and neurite extension, endothelial cell proliferation, endothelial cell 291 
migration and endothelial tubule formation in vitro. This paracrine activity has application in 292 
MSC-mediated therapies to promote tissue repair. Furthermore, the effects of the MSC 293 
secretome on neuronal and endothelial cells present at CNS lesion sites might help explain 294 
how MSC transplantation induces improved anatomical repair and functional outcomes in 295 
dogs with natural SCI. 296 
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Figure legends 625 
 626 
Fig. 1. Characterisation of canine mesenchymal stem cells (MSCs). (A) Representative 627 
images are shown of plastic adherent, fibroblastic cells under phase contrast microscopy prior 628 
to treatment with inducers of differentiation (top panel) and after inductions to become oil red 629 
O-positive adipocytic cells, alkaline phosphatase-positive osteoblastic cells,, and toluidine 630 
blue-stained cartilaginous extracellular matrix and cells, as indicated (positivity arrowed, 631 
bottom panels). Cell viability in all two-dimensional cultures was > 95%, but there was a loss 632 
of cell viability during the chondrogenic differentiation of MSCs in pellet cultures (visualised 633 
following Live/Dead staining and confocal microscopy; inset, bottom left panel). Scale bars = 634 
20 µm. (B) Representative histograms of flow cytometric analysis of canine MSCs following 635 
immunocytochemical staining for CD34, CD44, CD45 and CD90.  Immunoreactivity with 636 
irrelevant isotype-matched control antibodies is shown in blue, while immunoreactivity for 637 
each of the CD markers is shown in red. 638 
 639 
Fig. 2. Canine mesenchymal stem cells (MSCs) secrete factors that promote SH-SY5Y 640 
neuronal cell proliferation, neurite outgrowth and neuronal differentiation. (A) Representative 641 
images are shown of SH-SY5Y neuronal cells following culture for 3 days in the presence of 642 
canine MSC conditioned medium (MSC CM) or in control medium. As shown, there was 643 
clear evidence of increased cell numbers and neurite outgrowth (arrowed) in MSC CM 644 
compared with control cultures. Scale bars = 200 µm. (B) Representative images of SH-645 
SY5Y cells after 3 days of culture in the presence of canine MSC CM or in control medium 646 
and following immunocytochemical staining for the neuronal marker, βIII-tubulin. As shown, 647 
βIII-tubulin positive cells were seen in MSC CM to a much greater extent than under control 648 
conditions. (C) The Cell IQ imaging platform was used to quantify SH-SY5Y cell numbers 649 
and neurite outgrowth. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 650 
assays were also performed to assess viable cell numbers, and the proportion of cells 651 
immunopositive for βIII-tubulin was scored. There were significant increases in viable 652 
neuronal cell numbers (P < 0.01), the length of neurite outgrowth (P = 0.0055) and the 653 
proportions of βIII-tubulin immunopositive cells (P = 0.0002) in canine MSC CM compared 654 
to the control medium. Data has been presented as mean ± standard error.  **P < 0.01, *** P 655 
< 0.001.  656 
 657 
Fig. 3. Canine mesenchymal stem cells (MSCs) secrete factors that promote EA.hy926 658 
endothelial cell proliferation and cell migration. (A) Representative images are shown of 659 
EA.hy926 endothelial cell scratch assays. As shown, there was an increase in the extent of 660 
wound closure in canine MSC conditioned medium (MSC CM) compared with control 661 
medium after 2 days in culture. Scale bars = 200 µm. (B) Wound closure, cell division and 662 
cell migration was tracked using the Cell IQ live cell imaging platform, wherein digitised 663 
images were collected every 15 min over 2 days. Three-(4,5-dimethylthiazol-2-yl)-2,5-664 
diphenyltetrazolium bromide (MTT) assays were also performed to assess viable cell 665 
numbers. Top left panel: The rate of endothelial cell wound closure was significantly greater 666 
(P = 0.0409) in the presence of MSC CM (right line) vs. control media (blue line) over a 2-667 
day time course. Bottom left panel: There was a significant increase in the number of 668 
dividing endothelial cells (per image) (P = 0.0127) in the scratch wound assays in the 669 
presence of MSC CM (red line) vs. control medium (blue line). Top right panel: There was a 670 
significant increase in total distance that endothelial cells migrated over a 2-day period in 671 
MSC CM vs. control medium (P = 0.0001). Bottom right panel: There were significantly 672 
more viable endothelial cells present after 2 days in culture in canine MSC CM vs. control 673 
medium, as determined by MTT assay (P = 0.0019). Data has been presented as mean ± 674 
standard error.  **P < 0.01, ****P < 0.0001. 675 
 676 
Fig. 4. Canine mesenchymal stem cells (MSCs) secrete factors that promote EA.hy926 677 
endothelial tubule formation. EA.hy926 endothelial cells were seeded at 2x102 cells/well in 678 
96-well plates coated previously with Matrigel reduced growth factor and treated with canine 679 
MSC conditioned medium (MSC CM) or control medium.  (A) Representative images are 680 
shown of the growth pattern of EA.hy926 endothelial cells after 24 h in canine MSC CM vs. 681 
control medium. As shown, the EA.hy926 cells in canine MSC CM formed aggregates and 682 
tubes, which was not evident in control medium. Scale bars = 200 µm. (B) Image analysis 683 
demonstrated that there were significant increases in both the total tubule length (P = 0.0082) 684 
and total numbers of branch points (P = 0.0307) in canine MSC CM compared to control 685 
medium. Data has been shown as mean ± standard error. *P < 0.05, **P < 0.01.  686 
16-00402 1 
 2 
Canine mesenchymal stem cells are neurotrophic and angiogenic: An in vitro 3 
assessment of their paracrine activity  4 
 5 
 6 
I.R. Al Delfi a, J.J. Sheard a, C.R. Wood b, A. Vernallis a, J.F. Innes c, P. Myint c, W.E.B. 7 
Johnson b, * 8 
 9 
a Life and Health Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK 10 
b Department of Biological Sciences, Faculty of Medicine, Dentistry and Life Sciences, 11 
University of Chester, Parkgate Road, Chester, Cheshire CH1 4BJ, UK 12 
c Veterinary Tissue Bank Ltd, Brynkinalt Business Centre, Wrexham LL14 5NS, UK 13 
 14 
 15 
 16 
 17 
* Corresponding author: Tel.: +44 7745 616225. 18 
 E-mail address: eustace.johnson@chester.ac.uk (W.E.B. Johnson). 19 
20 
Manuscript
Click here to view linked References
Abstract 21 
Mesenchymal stem cells (MSCs) have been used in cell replacement therapies for 22 
connective tissue damage, but also can stimulate wound healing through paracrine activity. In 23 
order to further understand the potential use of MSCs to treat dogs with neurological 24 
disorders, this study examined the paracrine action of adipose-derived canine MSCs on 25 
neuronal and endothelial cell models.  26 
 27 
The culture-expanded MSCs exhibited a MSC phenotype according to plastic 28 
adherence, cell morphology, CD profiling and differentiation potential along mesenchymal 29 
lineages. Treating the SH-SY5Y neuronal cell line with serum-free MSC culture-conditioned 30 
medium (MSC CM) significantly increased SH-SY5Y cell proliferation, neurite outgrowth 31 
and immunopositivity for the neuronal marker βIII-tubulin. Treatment of the EA.hy926 32 
endothelial cell line with MSC CM significantly increased the rate of wound closure in 33 
endothelial cell scratch wound assays, which was associated with increased endothelial cell 34 
proliferation and migration. Furthermore, canine MSC CM induced endothelial tubule 35 
formation in EA.hy926 cells in a soluble basement membrane matrix. Hence, this study has 36 
demonstrated that adipose-derived canine MSC CM stimulated neuronal and endothelial cells 37 
probably through the paracrine activity of MSC-secreted factors. This supports the use of 38 
canine MSC transplants or their secreted products in the clinical treatment of dogs with 39 
neurological disorders and provides some insight into possible mechanisms of action. 40 
 41 
Keywords: Angiogenesis; Central nervous system repair; Mesenchymal stem/stromal cell; 42 
Nerve growth; Secretome43 
Introduction 44 
Mesenchymal stem cells (MSCs) were originally identified as stem/progenitor cells 45 
that differentiated to form connective tissues, e.g. as bone-forming osteoblasts and cartilage-46 
forming chondrocytes, and the bone marrow stroma supporting haemopoiesis (Friedenstein et 47 
al., 1974; Haynsworth et al., 1992; Pittenger et al., 1999). This led to MSCs being considered 48 
important candidates for cell replacement therapies for damaged connective tissues or to 49 
support bone marrow haemopoeitic stem cell transplantation (Young et al., 1998; Gupta et 50 
al., 2012; De Bari et al., 2013; Giannotti et al., 2013; Wu et al., 2013). However, it has 51 
become clear that MSCs play wider roles in tissue regeneration and wound healing as they 52 
secrete growth factors and cytokines that can stimulate endogenous cells present at wound 53 
sites (Chen et al., 2008; Park et al., 2009). This secretory function can augment tissue repair 54 
through trophic, anti-inflammatory or immunodulatory activity for various conditions, 55 
including heart disease (Gallini et al., 2015), liver damage (Berrardis et al., 2015; Owen and 56 
Newsome, 2015), skin wounds (Otero-Venas and Falanga, 2016) and central nervous system 57 
(CNS) damage (Teixeira et al., 2013). Furthermore, MSCs have been isolated from tissue 58 
sources other than bone marrow, including adipose tissues, which is an attractive source, due 59 
to its relative ease of removal (Sousa et al., 2014). The breadth of MSC activity and their 60 
ready availability has broadened the attractiveness of MSC-based therapies in regenerative 61 
medicines (Correa and Caplan, 2011).  62 
 63 
 The use of MSCs to promote wound healing after spinal cord injury (SCI) is a 64 
particular case in point. We and others have reported that human MSC secrete factors that 65 
promote neurite outgrowth (Neuhuber et al., 2005; Crigler L. et al., 2006; Wright et al., 2007, 66 
Nakano et al., 2010; Wright et al., 2010 and 2014) and endothelial cell proliferation and 67 
migration in vitro (Walter et al., 2015) and that MSC transplantation was associated with 68 
decreased inflammation, increased neural survival, increased axonal regeneration and 69 
improved functional recovery after SCI in vivo (Ankeny et al., 2004; Neuhuber et al., 2005; 70 
Himes et al., 2006; Nakajima et al., 2012). This research supports MSC transplantation as a 71 
cell therapy for various conditions, including CNS damage, with a number of human trials 72 
currently underway or in development. In dogs, MSC-based cell therapies for CNS damage, 73 
particularly SCI, also have been explored. In an experimental model of SCI, MSC transplants 74 
were associated with increased neural survival and repair, increased axonal conductance 75 
velocity, reduced inflammation and increased functional recovery (Lim et al., 2007; Ryu et 76 
al., 2012). MSC transplants similarly were associated with increased function in dogs 77 
suffering from natural SCI following intervertebral disc herniation (Chung et al., 2013; Penha 78 
et al., 2014; Sarmento et al., 2014; Besalti et al., 2015; Kim et al., 2016). Examining the 79 
efficacy of cell transplantation for naturally occurring CNS damage in dogs in this manner is 80 
an important step in the translation of experimental studies to human and animal cell 81 
therapies (Jeffery et al., 2006, 2011; Hoffman and Dow, 2016). However, for new cell 82 
therapies in dogs to be applied optimally and for this translational knowledge to human 83 
treatment to be complete, it is essential that researchers establish the mode of activity of 84 
canine MSCs. Therefore, in this study we examined whether canine MSCs isolated from 85 
adipose tissue exert a neurotrophic and angiogenic activity through their secretome. 86 
 87 
Materials and methods 88 
MSC isolation and growth 89 
Institutional approval was provided for this study (University of Chester Faculty of 90 
Science and Engineering Research Ethics Committee: 060/16/CW/BS, 18 May 2016). 91 
Following owner and veterinary surgeon consent for research, canine adipose tissue-derived 92 
MSCs were isolated and cultured from surgically extracted inguinal fat pads of dogs 93 
undergoing MSC transplantations for the treatment of joint pathology. MSCs were isolated 94 
by collagenase digestion of the tissue for 2 h at 37 oC (0.2% Type A Collagenase, 95 
Worthington Biochemical), selected through their preferential adhesion to tissue culture 96 
plastic, as reported previously (Vieira et al., 2010; Kohli et al., 2015), and cultured in 97 
Dulbecco’s modified Eagle medium/F12 (DMEM/F12) supplemented with 10% fetal bovine 98 
serum and 1% penicillin/ streptomycin (Life Technologies) in a humidified atmosphere of 5% 99 
CO2 with 95% air at 37 oC. Cultures were routinely passaged at 70-80% confluence using 100 
0.25% trypsin-EDTA (Life Technologies). All experimental procedures were performed 101 
using MSC cultures at passages 3-5.  102 
 103 
MSC characterisation 104 
MSC phenotype was examined according to the International Society for Cell 105 
Therapy (ISCT) criteria (Dominici et al., 2006), which are as follows: (1) cell adherence to 106 
tissue culture plastics; (2) adipogenic, osteogenic and chondrogenic differentiation potential; 107 
and (3) an immunoprofile for CD markers that includes immunonegativity for CD34 and 108 
CD45 and immunopositivity for CD44 and CD90, as assessed by flow cytometry (Appendix: 109 
Supplementary material).  110 
 111 
MSC culture-conditioned medium (MSC CM) 112 
MSCs were seeded at a density of 1.5 x 106 cells in T75 tissue culture flasks in 113 
standard culture medium for 24 h to permit cell adhesion, then the medium was discarded and 114 
the cultures washed in PBS prior to feeding with 15 mL of DMEM/F12 medium 115 
supplemented with 1% ITS, 1% non-essential amino acids and 1% penicillin/streptomycin, 116 
but without any serum present. Cultures were then incubated at 37 ºC in a humidified 117 
atmosphere of 5% CO2 for 3 days, when the MSC culture-conditioned medium (MSC CM) 118 
was collected, filtered with a sterile filter (0.20 µm, Minisart), aliquoted and stored at -80 ºC. 119 
Control medium (i.e. serum free DMEM/F12 with the same supplements, but with no cells 120 
present) was similarly incubated in T75 culture flasks for 3 days, harvested, filtered and 121 
stored. Under serum-free conditions, there was no evident loss of cell viability and greater 122 
than 98% of cells in all cultures were viable at day 3 (by trypan blue exclusion).  123 
 124 
The effects of MSC CM on SH-SY5Y neuronal cells  125 
The human neuroblastoma cell line SH-SY5Y was used to assess neurotrophic 126 
activity of canine MSC CM, as has been performed previously with human MSC CM 127 
(Wright et al., 2010; Pires et al., 2014; Appendix: Supplementary material). This was due to a 128 
lack of available canine neuronal models, but also because we and other researchers have 129 
found similar responses to MSC secretomes in cell assays using MSCs and responder cells of 130 
the same and different species, i.e. humans, chickens and rodents (Neuhuber et al., 2005; 131 
Wright et al., 2010; Pires et al., 2014) suggesting conservation of paracrine activity.   132 
 133 
The effects of MSC CM on EA.hy926 endothelial cells 134 
The human Ea.hy926 endothelial cell line was used as a model to examine any 135 
angiogenic activity of canine MSC CM, due to a lack of available canine endothelial cells and 136 
also because these cells have been used previously to test human MSC CM (Walter et al., 137 
2015). EA.hy926 cell assays were performed to measure endothelial cell proliferation, 138 
endothelial cell migration and endothelial tubule formation (Appendix: Supplementary 139 
material). 140 
 141 
Statistical analysis 142 
At least three independent experiments were performed for all analysis, i.e. using 143 
MSCs and MSC CM derived from at least three different dogs vs. at least three separate 144 
control media with 3-5 replicates for each experiment. Data were examined for normal 145 
distributions and then analysed by two-way ANOVA, independent samples Student’s t tests 146 
or Mann Whitney U tests, according to whether data was distributed normally or not. All data 147 
has been presented as mean ± standard error. P values <0.05 was considered statistically 148 
significant. Statistical analysis was performed using GraphPad Prism7 (GraphPad Software). 149 
 150 
Results 151 
 Characterisation of canine MSCs 152 
At passage 3-5, cultures of canine MSCs were plastic-adherent, displayed a stromal 153 
appearance and had the capacity to undergo differentiation towards adipogenic, osteogenic 154 
and chondrogenic lineages (Fig. 1A). For adipogenic and osteogenic differentiation, there 155 
was no evident loss of cell viability, however for chondrogenic pellet cultures some cell death 156 
was apparent, but nonetheless there was also clear evidence of extracellular metachromatic 157 
staining with toluidine blue, indicative of glycosaminoglycan deposition and chondrogenic 158 
differentiation. CD immunoprofiling demonstrated that canine MSCs were largely 159 
immunonegative for CD34 (0.3 ± 0.6%) and CD45 (0.1 ± 0.3%) and immunopositive for 160 
CD44 (87.7 ± 9.3%) and CD90 (94.1 ± 9.7%; Fig. 1B). These results demonstrate that the 161 
canine cells that had been culture-expanded from adipose tissue met the necessary criteria of 162 
the ISCT (Dominici et al., 2006) to be considered MSCs. 163 
 164 
Canine MSC secreted factors promote SH-SY5Y cell proliferation and neuronal 165 
differentiation 166 
Treating SH-SY5Y cells with canine MSC CM promoted their proliferation and 167 
neuronal differentiation, as determined by viable cell numbers, neurite outgrowth and 168 
immunoreactivity for βIII-tubulin (Fig. 2). There was an increase in the number of SH-SY5Y 169 
cells present, and in their extent of neurite outgrowth (Fig. 2A), which were immunopositive 170 
for βIII-tubulin (Fig. 2B) in MSC CM vs. control media. SH-SY5Y neurite length/cell and 171 
the proportions of SH-SY5Y cells that were βIII-tubulin immunopositive were significantly 172 
greater in MSC CM than in control medium (Fig. 2C). The increase in SH-SY5Y cell number 173 
in MSC CM vs. control medium was also significant and confirmed by 3-(4,5-174 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays (Fig. 2C). 175 
 176 
Canine MSC secreted factors promote EA.hy926 endothelial cell migration, proliferation and 177 
tubule formation  178 
The effects of canine MSC CM on EA.hy926 cells were examined by scratch assay, 179 
time-lapse live cell image analysis, MTT assay and tubule formation with Matrigel. In 180 
EA.hy926 endothelial scratch wound assays, wound closure was markedly increased in MSC 181 
CM compared to control media (Fig. 3A). Using live cell image analysis, we found that 182 
EA.hy926 cells closed the scratch wounds significantly more quickly in MSC CM vs. control 183 
media by a combination of increased cell migration and cell proliferation (Fig. 3B). The 184 
trophic effects of MSC CM on EA.hy926 endothelial cell proliferation were confirmed by 185 
MTT assays for the numbers of viable cells, which was significantly increased after 2 days 186 
culture in MSC CM compared with control media (Fig. 3B). We then tested whether MSC 187 
CM could promote blood vessel formation, as delineated by endothelial tubule formation in 188 
Matrigel assays and digitised image analysis (Fig. 4). As shown (Fig. 4A), culturing 189 
EA.hy926 endothelial cells on Matrigel did not give rise to any marked tubule formation 190 
unless MSC CM was present, in which case both the total length of the endothelial tubules 191 
that formed and the number of endothelial tubule branch points present were significantly 192 
increased in MSC CM compared to control media (Fig. 4B). 193 
 194 
Discussion 195 
MSCs have been investigated for their wound healing activity, with potential 196 
applications for a wide variety for conditions including CNS damage. MSCs exert paracrine 197 
effects on cells involved in CNS repair, including neuronal cells, endothelial cells and 198 
immune cells (Neuhuber et al., 2005; Crigler et al., 2006; Wright et al., 2007; Wright et al., 199 
2010; Nakajima et al., 2012; Wright et al., 2014; Walter et al., 2015). Furthermore, MSC 200 
transplantation in animal models of SCI was associated with enhanced neural regeneration, 201 
modulation of immune responses and improved functional outcomes (Ankeny et al., 2004; 202 
Neuhuber et al., 2005; Himes et al., 2006; Nakajima et al., 2012). Hence, MSC transplants 203 
are considered an attractive treatment option to help overcome CNS damage, particularly SCI 204 
(Wright et al., 2011). 205 
 206 
Dogs, like humans, can suffer from SCI and paralysis, either through accidental 207 
trauma or following herniation of the intervertebral disc. Furthermore, other researchers have 208 
recently demonstrated that transplantation of autologous culture-expanded olfactory 209 
ensheathing cells (OECs) might be of benefit to dogs with SCI (Granger et al., 2012). This 210 
not only is of use to veterinary medicine, but also helps inform the development of clinical 211 
human SCI studies (Jeffery et al., 2006, 2011). Therefore, with a view to developing MSC 212 
transplants for dogs with CNS damage and to further understand the potential mechanisms of 213 
action of MSC following transplantation, we investigated whether canine MSCs exerted 214 
paracrine wound healing activities similar to human and rodent MSCs.  215 
 216 
After initially characterizing MSCs from the inguinal fat pads of dogs according to 217 
the ISCT criteria (Dominici et al., 2006), we used established in vitro assays with responder 218 
cell lines to test their paracrine activity. We report that MSC CM was trophic for SH-SY5Y 219 
neuronal cells, and stimulated neurite outgrowth and neuronal differentiation. MSC CM also 220 
was trophic for EA.hy926 endothelial cells, enhanced their migratory behaviour and 221 
stimulated endothelial tubule formation, all of which indicate angiogenic activity, although 222 
clearly further in vivo testing would help confirm this  (Auerbach et al., 2003). These data 223 
support the application of MSC transplantation in dogs with SCI, as well as other CNS 224 
injuries, as enhanced neuronal survival, axonal growth and the appropriate regulation of 225 
angiogenesis are thought to represent important aspects of repair processes (Oudega et al., 226 
2012; Quertainmont et al., 2012). 227 
 228 
The mechanisms of action of the canine MSC secretome warrant further investigation. 229 
In other species, MSCs are known to secrete a plethora of growth factors, cytokines and 230 
extracellular matrix (ECM) components (Park et al., 2009; Walter et al., 2010, 2015).  These 231 
include a variety of soluble neurotrophic factors, including nerve growth factor, brain-derived 232 
neurotrophic factor and glial-derived neurotrophic factor, as well as pleiotrophic factors that 233 
also can stimulate nerve outgrowth, such as fibroblast growth factors 1 and 2 (FGF1 and 234 
FGF2) and stromal derived factor 1 (Crigler et al., 2006; Wilkins et al., 2009; Nakano et al., 235 
2010; Hseih et al., 2013; Kingham et al., 2014; Lin et al., 2014). Similarly, MSCs are known 236 
to secrete soluble angiogenic factors, including FGFs, hepatocyte growth factor and the 237 
highly potent vascular endothelial growth factor (Rehman et al., 2004; Cai et al., 2007). In 238 
addition, at least some of the ECM components that have been identified in human MSC CM, 239 
particularly fibronectin and laminin, form a stimulatory substratum for nerve growth and also 240 
endothelial cells (Kapur and Katz, 2013; Walter et al., 2010, 2015). The identification of 241 
growth factors and ECM in the secretome of canine MSCs is somewhat hampered by a lack 242 
of canine specific antibodies, but it is highly likely that many of the factors present in the 243 
MSC secretomes of other species are similarly secreted by canine MSCs. Additionally, they 244 
could play active roles in the neurostimulatory and angiogenic effects seen in SH-SY5Y 245 
neuronal cells and EA.hy926 endothelial cells. A similar profile of growth factors and ECM 246 
components has been reported in MSC secretomes with cells cultured from a variety of tissue 247 
sources (Walter et al., 2010, 2015; Kapur and Katz, 2013; Bronckaers et al., 2014). Also, 248 
there is a high degree of conservation across species for at least some growth factors and 249 
cytokines that have been examined at the molecular level (Wen et al., 1993; Scheerlinck, 250 
1999). Nonetheless, one recent study found species-specific differences in the secretome and 251 
paracrine activity of canine and equine MSCs, particularly when cultured in serum free 252 
conditions (Clarke et al., 2016). Therefore, although it might be considered more likely that 253 
the canine MSC secretome would have even greater trophic effects on canine responder cells, 254 
a potential caveat to our study is that we tested canine MSC secretomes on human responder 255 
cell lines only. Further studies of canine neuronal and endothelial cells, as they become 256 
available, and the identification of MSC secreted factors in MSC CM, are required. 257 
 258 
In veterinary medicine, the uptake of MSC-based therapies has been relatively low, 259 
although canine MSC transplants were used recently in the treatment of some natural injury 260 
and disease conditions, including tendon repair (Case et al., 2013), osteoarthritis (Black et al., 261 
2007, 2008; Vilar et al., 2013, 2014; Cuevo et al., 2014), inflammatory bowel disease (Perez-262 
Merino et al., 2015a,b) and non-infectious CNS inflammation (Zeira et al., 2015). There also 263 
have been a number of studies of MSC transplants in canine SCI. In the clinical studies of 264 
SCI to date, MSC transplants have been associated with some benefits including improved 265 
gait and neurological function (Penha et al., 2014; Sarmento et al., 2014; Besalti et al., 2015; 266 
Kim et al., 2016). However, the mechanisms of action for these reported benefits remain 267 
poorly understood. In rodent models of SCI, MSC transplants have been suggested to exert a 268 
wide variety of effects that might enhance spinal cord repair and function (Ide et al., 2010; 269 
Vaquero and Zurita 2011; Teixeira et al., 2013), including their differentiation to form 270 
replacement neural cells (Deng et al., 2014), albeit contentiously (Wright et al., 2011); 271 
immunomodulatory/anti-inflammatory activity and increased neuronal survival (Ankeny et 272 
al., 2004; Crigler et al., 2006; Nakajima et al., 2012), directing axons that bridge across the 273 
SCI lesion site (Ankeny et al., 2004); secretion of neurotrophic factors and angiogenic factors 274 
to enhance axonal regeneration (Ankeny et al., 2004; Neuhuber et al., 2005; Lu P et al., 2005; 275 
Nakajima et al., 2012); and angiogenic responses (Zeng et al., 2011; Kingham et al., 2014). 276 
Here, to our knowledge, our study has provided the first evidence that canine MSCs promote 277 
nerve growth and endothelial cell proliferation, migration and tubule formation, probably 278 
through the secretion of neurotrophic and angiogenic factors. These findings support the 279 
hypothesis that MSC transplants can promote increased neuronal function in dogs with CNS 280 
damage, including SCI, due to their paracrine activity on nerves and blood vessels in the 281 
vicinity of the wound site. Further, this study supports the concept that cell transplants in 282 
dogs with SCI, whether MSCs or OECS, provide an important natural model for the 283 
development of human cell-based therapies.  284 
  285 
Conclusions  286 
In this study, we have demonstrated for the first time that canine MSCs stimulate 287 
neuronal growth and neurite extension, endothelial cell proliferation, endothelial cell 288 
migration and endothelial tubule formation in vitro. This paracrine activity has application in 289 
MSC-mediated therapies to promote tissue repair. Furthermore, the effects of the MSC 290 
secretome on neuronal and endothelial cells present at CNS lesion sites might help explain 291 
how MSC transplantation induces improved anatomical repair and functional outcomes in 292 
dogs with natural SCI. 293 
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Figure legends 622 
 623 
Fig. 1. Characterisation of canine mesenchymal stem cells (MSCs). (A) Representative 624 
images are shown of plastic adherent, fibroblastic cells under phase contrast microscopy prior 625 
to treatment with inducers of differentiation (top panel) and after inductions to become oil red 626 
O-positive adipocytic cells, alkaline phosphatase-positive osteoblastic cells,, and toluidine 627 
blue-stained cartilaginous extracellular matrix and cells, as indicated (positivity arrowed, 628 
bottom panels). Cell viability in all two-dimensional cultures was > 95%, but there was a loss 629 
of cell viability during the chondrogenic differentiation of MSCs in pellet cultures (visualised 630 
following Live/Dead staining and confocal microscopy; inset, bottom left panel). Scale bars = 631 
20 µm. (B) Representative histograms of flow cytometric analysis of canine MSCs following 632 
immunocytochemical staining for CD34, CD44, CD45 and CD90.  Immunoreactivity with 633 
irrelevant isotype-matched control antibodies is shown in blue, while immunoreactivity for 634 
each of the CD markers is shown in red. 635 
 636 
Fig. 2. Canine mesenchymal stem cells (MSCs) secrete factors that promote SH-SY5Y 637 
neuronal cell proliferation, neurite outgrowth and neuronal differentiation. (A) Representative 638 
images are shown of SH-SY5Y neuronal cells following culture for 3 days in the presence of 639 
canine MSC conditioned medium (MSC CM) or in control medium. As shown, there was 640 
clear evidence of increased cell numbers and neurite outgrowth (arrowed) in MSC CM 641 
compared with control cultures. Scale bars = 200 µm. (B) Representative images of SH-642 
SY5Y cells after 3 days of culture in the presence of canine MSC CM or in control medium 643 
and following immunocytochemical staining for the neuronal marker, βIII-tubulin. As shown, 644 
βIII-tubulin positive cells were seen in MSC CM to a much greater extent than under control 645 
conditions. (C) The Cell IQ imaging platform was used to quantify SH-SY5Y cell numbers 646 
and neurite outgrowth. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 647 
assays were also performed to assess viable cell numbers, and the proportion of cells 648 
immunopositive for βIII-tubulin was scored. There were significant increases in viable 649 
neuronal cell numbers, the length of neurite outgrowth and the proportions of βIII-tubulin 650 
immunopositive cells in canine MSC CM compared to the control medium. Data has been 651 
presented as mean ± standard error.  **P< 0.01, *** P< 0.001.  652 
 653 
Fig. 3. Canine mesenchymal stem cells (MSCs) secrete factors that promote EA.hy926 654 
endothelial cell proliferation and cell migration. (A) Representative images are shown of 655 
EA.hy926 endothelial cell scratch assays. As shown, there was an increase in the extent of 656 
wound closure in canine MSC conditioned medium (MSC CM) compared with control 657 
medium after 2 days in culture. Scale bars = 200 µm. (B) Wound closure, cell division and 658 
cell migration was tracked using the Cell IQ live cell imaging platform, wherein digitised 659 
images were collected every 15 min over 2 days. Three-(4,5-dimethylthiazol-2-yl)-2,5-660 
diphenyltetrazolium bromide (MTT) assays were also performed to assess viable cell 661 
numbers. Top left panel: The rate of endothelial cell wound closure was significantly greater 662 
in the presence of MSC CM (right line) vs. control media (blue line) over a 2-day time 663 
course. Bottom left panel: There was a significant increase in the number of dividing 664 
endothelial cells (per image) in the scratch wound assays in the presence of MSC CM (red 665 
line) vs. control medium (blue line). Top right panel: There was a significant increase in total 666 
distance that endothelial cells migrated over a 2-day period in MSC CM vs. control medium. 667 
Bottom right panel: There were significantly more viable endothelial cells present after 2 668 
days in culture in canine MSC CM vs. control medium, as determined by MTT assay. Data 669 
has been presented as mean ± standard error.  **P< 0.01, ****P< 0.0001. 670 
 671 
Fig. 4. Canine mesenchymal stem cells (MSCs) secrete factors that promote EA.hy926 672 
endothelial tubule formation. EA.hy926 endothelial cells were seeded at 2x102 cells/well in 673 
96-well plates coated previously with Matrigel reduced growth factor and treated with canine 674 
MSC conditioned medium (MSC CM) or control medium.  (A) Representative images are 675 
shown of the growth pattern of EA.hy926 endothelial cells after 24 h in canine MSC CM vs. 676 
control medium. As shown, the EA.hy926 cells in canine MSC CM formed aggregates and 677 
tubes, which was not evident in control medium. Scale bars = 200 µm. (B) Image analysis 678 
demonstrated that there were significant increases in both the total tubule length and total 679 
numbers of branch points in canine MSC CM compared to control medium. Data has been 680 
shown as mean ± standard error. *P< 0.05, **P< 0.01.  681 
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Highlights 
x Mesenchymal stem cells (MSCs) can be isolated and cultured from adipose 
tissue biopsies from dogs 
x Canine MSCs secrete factors to stimulate neuronal outgrowth and endothelial 
proliferation, migration and tubule formation  
x Canine MSCs and secretomes may promote wound repair following 
transplants in dogs with natural spinal cord injury 
 
 
*Highlights (for review)
Revision note 
Thank you for the advice re: including P values where we have indicated significance 
in the manuscript. These values have now been added, with required additions to the 
abstract, results, and figure legends. Where cell proliferation was discussed in a single 
phrase, e.g. “there was a significant increased in SH-SY5Y cell proliferation”, which 
was assessed by numbers of dividing cells and MTT assays, the P value was indicated 
as being P < 0.01, for simplicity, rather than giving each P value for the number of 
dividing cells and MTT. Where cell division or MTT results are described individually, 
we have given the appropriate P value.  
 
*Revision Note
Dear Editors, 
 
Thank you for your further consideration of our manuscript for publication in The 
Veterinary Journal and for the positive outcome. We are very happy that the 
reviewers are satisfied with the revised version and grateful to the Scientific Editor, 
Makoto Bonkobara, for his further editorial input in preparing the manuscript for 
publication. We have made the required changes suggested and these are incorporated 
into the two updated files now re-submitted: 
 
1. 16-00402R2 edited MB 180816 R3.docx 
The manuscript text. 
 
2. e-only supplementary materialR3.docx 
The revised Supplementary material 
 
The detailed response to the required editorial changes is listed below, in red text. I 
hope that the paper is now ready for publication in TVJ.  
 
Best regards, 
Eustace 
 
 
Ms. No. YTVJL-D-16-00402R2 
Canine mesenchymal stem cells are neurotrophic and angiogenic: an in vitro 
assessment of their paracrine activity for application in spinal cord repair 
The Veterinary Journal 
 
Editorial Comments: 
 
Dear Dr. William Eustace Johnson, 
 
Thank you for resubmitting this manuscript to be considered further for publication in 
The Veterinary Journal. Your paper has been re-examined by two previous referees 
and both reviewers are satisfied with your revision. I have now edited the manuscript.  
 
Please proof-read the manuscript 16-00402R2 edited MB 180816 (which should be 
downloaded from the File Inventory on the Elsevier Electronic System, EES) to 
ensure that editorial changes have not altered the meaning. 
We have proof read the manuscript and agree to all changes.  
 
Please modify the following points. 
 
- Please shorten the background part of the abstract. 
 
We have shortened the background information such that the Abstract is reduced from 
246 words to 206 words.  
 
Specifically the text below has been removed: 
 
“Mesenchymal stem cells (MSCs) differentiate into adipocytes, chondrocytes and 
*Revision Note
osteoblasts and have been used to repair connective tissue damage in cell replacement 
therapies. However, MSC-mediated tissue repair/regeneration is also associated with 
their secretion of factors that can act in a paracrine fashion to stimulate endogenous 
cells at wound sites. In order to further understand the potential use of MSCs to treat 
dogs with neurological disorders, such as spinal cord injury (SCI), this study has 
examined the paracrine activity of canine MSCs isolated and cultured from inguinal 
fat pads on neuronal and endothelial cell models.” 
(94 WORDS) 
 
And this has been replaced with the following: 
 
“Mesenchymal stem cells (MSCs) have been used in cell replacement therapies for 
connective tissue damage, but also can stimulate wound healing through paracrine 
activity. In order to further understand the potential use of MSCs to treat dogs with 
neurological disorders, this study has examined the paracrine action of adipose-
derived canine MSCs on neuronal and endothelial cell models.” 
(57 WORDS) 
 
 
- Institutional approval of the experiment: Please state the date of approval along with 
the reference number (e.g. 060/16/CW/BS, 18 August 2016). 
We have now added the date of Institutional approval to the Methods section. 
 
- Main text, results section: Fig. 2, A to C should appear in alphabetical order (A, B, 
C not A, C, B). Fig. 3 is also the same. 
 
The Results text has been edited to address each figure in alphabetical order. 
Specifically the following text has been included: 
 
For Fig 2: 
“There was an evident increase in the number of SH-SY5Y cells present, and in their 
extent of neurite outgrowth (Fig. 2A), which were immunopositive for βIII-tubulin 
(Fig. 2B) in MSC CM versus control media. SH-SY5Y neurite length/cell and the 
proportions of SH-SY5Y cells that were βIII-tubulin immunopositive were 
significantly greater in MSC CM compared to control medium (Fig. 2C). The increase 
in SH-SY5Y cell number in MSC CM vs. control medium was also significant and 
confirmed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assays (Fig. 2C).” 
 
For Fig 3: 
“In EA.hy926 endothelial scratch wound assays, wound closure was markedly 
increased in MSC CM compared to control media (Fig. 3A). Using live cell image 
analysis, we found that EA.hy926 cells closed the scratch wounds significantly more 
quickly in MSC CM versus control media by a combination of increased cell 
migration and cell proliferation (Fig. 3B). The trophic effects of MSC CM on 
EA.hy926 endothelial cell proliferation were confirmed by MTT assays for the 
numbers of viable cells, which was shown to be significantly increased after two days 
culture in MSC CM compared with control media (Fig. 3B).” 
 
- Please define all abbreviations used in each figure legend. 
All abbreviations have now been defined. 
 
- Supplementary material: Please use 12 point Times font throughout the text. Please 
ensure that the text is formatted according to the style of The Veterinary Journal. 
The Supplementary material has been amended so that the text is 12 point Times font 
throughout. We have also amended the text to the style of TVJ by changing various 
needed aspects of the nomenclature, units, and abbreviations, e.g. “mL” rather than 
ml, “37 oC” rather than 37oC, “vs.” rather than versus; “min” rather than minutes, as 
required. 
 
